335254-95-0

Basic information

• Product Name: Carbamic acid, [2-nitro-4-(2-thienyl)phenyl]-, 1,1-dimethylethyl ester
• CAS NO: 335254-95-0
• Molecular Formula: C15H16N2O4S
• Molecular Weight: 320.369
• Mol File: 335254-95-0.mol
• Article Data: 17

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [2-nitro-4-(2-thienyl)phenyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [2-nitro-4-(2-thienyl)phenyl]-, 1,1-dimethylethyl ester(335254-95-0)
• EPA Substance Registry System: Carbamic acid, [2-nitro-4-(2-thienyl)phenyl]-, 1,1-dimethylethyl ester(335254-95-0)

Safety Data

• Hazardous Substances Data: 335254-95-0(Hazardous Substances Data)

Upstream product

• 6165-68-0 thiophene boronic acid 
• 327046-79-7 tert-butyl (4-bromo-2-nitrophenyl)carbamate 
• 335254-69-8 1-(tert-butoxycarbonyl)amino-4-iodo-2-nitrobenzene 
• 73183-34-3 bis(pinacol)diborane 
• 88-74-4 2-nitro-aniline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 875-51-4 4-Bromo-2-nitroaniline 

Downstream Products

• 937728-82-0 tert-butyl N-(2-(6-chloronicotinamido)-4-(thiophen-2-yl)phenyl)carbamate 

Relevant articles and documents

Ring size changes in the development of class I HDAC inhibitors

Five pathways involving different ring structures led to generation of fourteen thienylbenzamides (7–20) which display the structure-activity relationships of class I HDAC inhibitors. All the synthesised compounds inhibit HDAC1 and HDAC2 selectively over other isoforms and many inhibit DLD1 and HCT116 cells more effectively than a parent compound. Compounds 8 and 16 inhibit HCT116 cells by activation of the apoptosis pathway.

HDAC DEGRADER

The disclosure provides compounds of formula (I). The compounds may be used to degrade the Histone Deacetylase (HDAC) family of enzymes, particularly HDAC1, 2 and 3 that exist in corepressor complexes. Accordingly, the compounds may

Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study

Previously, we reported the discovery of a series of N-hydroxycinnamamide-based HDAC inhibitors, among which compound 11y exhibited high HDAC1/3 selectivity. In this current study, structural derivatization of 11y led to a new series of benzamide based HDAC inhibitors. Most of the compounds exhibited high HDACs inhibitory potency. Compound 11a (with 4-methoxybenzoyl as N-substituent in the cap and 4-(aminomethyl) benzoyl as the linker group) exhibited selectivity against HDAC1 to some extent, and showed potent antiproliferative activity against several tumor cell lines. In?vivo studies revealed that compound 11a displayed potent oral antitumor activity in both hematological tumor cell U937 xenograft model and solid tumor cell HCT116 xenograft model with no obvious toxicity. Further modification of benzamide 3, 11a and 19 afforded new thienyl and phenyl compounds (50a, 50b, 63a, 63b and 63c) with dramatic HDAC1 and HDAC2 dual selectivity, and the fluorine containing compound 56, with moderate HDAC3 selectivity.